MX2022002211A - Composiciones y metodos para tratar infecciones virales. - Google Patents

Composiciones y metodos para tratar infecciones virales.

Info

Publication number
MX2022002211A
MX2022002211A MX2022002211A MX2022002211A MX2022002211A MX 2022002211 A MX2022002211 A MX 2022002211A MX 2022002211 A MX2022002211 A MX 2022002211A MX 2022002211 A MX2022002211 A MX 2022002211A MX 2022002211 A MX2022002211 A MX 2022002211A
Authority
MX
Mexico
Prior art keywords
methods
viral infections
compositions
viral
treating viral
Prior art date
Application number
MX2022002211A
Other languages
English (en)
Spanish (es)
Inventor
Serhat Gumrukcu
Original Assignee
G Tech Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio Llc filed Critical G Tech Bio Llc
Publication of MX2022002211A publication Critical patent/MX2022002211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022002211A 2019-08-29 2020-08-28 Composiciones y metodos para tratar infecciones virales. MX2022002211A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893460P 2019-08-29 2019-08-29
US202062968387P 2020-01-31 2020-01-31
US202062976491P 2020-02-14 2020-02-14
US202062985597P 2020-03-05 2020-03-05
PCT/US2020/048370 WO2021041787A1 (fr) 2019-08-29 2020-08-28 Compositions et méthodes pour le traitement d'infections virales

Publications (1)

Publication Number Publication Date
MX2022002211A true MX2022002211A (es) 2022-05-24

Family

ID=74686046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002211A MX2022002211A (es) 2019-08-29 2020-08-28 Composiciones y metodos para tratar infecciones virales.

Country Status (11)

Country Link
EP (1) EP4022072A4 (fr)
JP (1) JP2022546402A (fr)
KR (1) KR20220095183A (fr)
CN (1) CN114761566A (fr)
AU (1) AU2020335886A1 (fr)
BR (1) BR112022003814A2 (fr)
CA (1) CA3149041A1 (fr)
IL (1) IL290826A (fr)
MX (1) MX2022002211A (fr)
WO (1) WO2021041787A1 (fr)
ZA (1) ZA202202370B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220282279A1 (en) * 2021-03-06 2022-09-08 Serhat Gumrukcu Compositions and methods for treating and preventing coronavirus infections
WO2023220086A1 (fr) * 2022-05-13 2023-11-16 Suntec Medical, Inc. Méthode de traitement d'une maladie infectieuse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
WO2012170431A2 (fr) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Systèmes perfectionnés de commutation génique
US10072047B2 (en) * 2014-06-20 2018-09-11 Drexel University Tagged hepadnavirus e antigen and its use in screening antiviral substances

Also Published As

Publication number Publication date
ZA202202370B (en) 2022-11-30
WO2021041787A1 (fr) 2021-03-04
EP4022072A1 (fr) 2022-07-06
JP2022546402A (ja) 2022-11-04
EP4022072A4 (fr) 2023-09-06
AU2020335886A1 (en) 2022-03-17
KR20220095183A (ko) 2022-07-06
BR112022003814A2 (pt) 2022-05-24
CN114761566A (zh) 2022-07-15
CA3149041A1 (fr) 2021-03-04
IL290826A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12017501792A1 (en) Recombinant binding proteins and their use
MX2018014573A (es) Vacuna contra el virus del zika.
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12021500001A1 (en) Antibodies that target hiv gp120 and methods of use
MX2022002211A (es) Composiciones y metodos para tratar infecciones virales.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2023004595A (es) Proteinas de fusion interleucina-2-fc y metodos de uso.
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
CA3009928A1 (fr) Vaccin contre le virus de l'encephalite equine base sur un virus modifie de la vaccine ankara (mva) recombinant
MX2022011394A (es) Composiciones y metodos para la induccion de una respuesta inmune.
WO2020035609A3 (fr) Compositions immunogènes et leurs utilisations
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
WO2020028719A3 (fr) Compositions comprenant le virus 1 de l'herpès simplex pour les utiliser dans des procédés de traitement et de prévention du cancer
MX2023007319A (es) Vacunas de acido nucleico.
MX2022002231A (es) Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
PH12017500109A1 (en) Composition for treating cancerous cells and a method therefor
WO2021019235A3 (fr) Composition antigénique d'hantavirus
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
ZA202301221B (en) Compositions and methods related to ebola virusvaccines
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с